A phase 2 study of vatalanib in metastatic melanoma patients

European Journal of Cancer

Volumn 46, Issue 15, 2010, Pages 2671-2673

  Cook, Natalie ^a   Basu, Bristi ^a   Biswas, Swethajit ^a   Kareclas, Paula ^a   Mann, Colette ^a   Palmer, Cheryl ^a   Thomas, Anne ^b   Nicholson, Steve ^b   Morgan, Bruno ^b   Lomas, David ^a   Sirohi, Bhawna ^a   Mander, Adrian P ^d   Middleton, Mark ^c   Corrie, Pippa G ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

Colorectal cancer; NGR hTNF; Vascular targeting agent

Indexed keywords

LIVER ENZYME; VATALANIB;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; HYPERTENSION; MALE; MELANOMA; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PHTHALAZINES; PYRIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957192895     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.07.014     Document Type: Article

References (10)

1. H. Tsao, M.B. Atkins, and A.J. Sober Management of cutaneous melanoma N Engl J Med 351 10 2004 998 1012 (Pubitemid 39166263)
2. K.A. Varker, J.E. Biber, and C. Kefauver A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma Ann Surg Oncol 14 8 2007 2367 2376 (Pubitemid 47174913)
3. T. Eisen, T. Ahmad, and K.T. Flaherty Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Br J Cancer 95 5 2006 581 586 (Pubitemid 44325897)
4. Jea Fruehauf Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study J Clin Oncol 2008 26 [abstract 9006]
5. J.M. Wood, G. Bold, and E. Buchdunger PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 8 2000 2178 2189 (Pubitemid 30225181)
6. T.Cea Gauler Phase II open-label study to investigate efficacy and safety of PTK787 orally administered once daily at 1250mg as second line monotherapy in patients with stage IIIB or IV non-small cell lung cancer Proc Am Soc Clin Oncol 24 2006 274s [abstract 5075]
7. A.L. Thomas, T. Trarbach, and C. Bartel A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer Ann Oncol 18 4 2007 782 788 (Pubitemid 46523285)
8. C. Conrad A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM) J Clin Oncol 22 14s 2004 1512
9. B. Morgan, J.F. Utting, and A. Higginson A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging Br J Cancer 94 10 2006 1420 1427 (Pubitemid 43772276)
10. S.S. Agarwala, U. Keilholz, and E. Gilles LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951) Eur J Cancer 45 10 2009 1807 1814